{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T01:44:27Z","timestamp":1648777467183},"reference-count":45,"publisher":"Pharmaceutical Society of Japan","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2015]]},"DOI":"10.1248\/bpb.b14-00745","type":"journal-article","created":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T10:52:16Z","timestamp":1427885536000},"page":"587-593","source":"Crossref","is-referenced-by-count":4,"title":["Administration of Olanzapine as an Antiemetic Agent Changes Glucose Homeostasis in Cisplatin-Treated Rats"],"prefix":"10.1248","volume":"38","author":[{"given":"Maiko","family":"Machida","sequence":"first","affiliation":[{"name":"Division of Pharmacotherapy, Hokkaido Pharmaceutical University School of Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Miyamura","sequence":"additional","affiliation":[{"name":"Department of Pharmacological Sciences, School of Pharmaceutical Sciences, Health Sciences University of Hokkaido"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Machida","sequence":"additional","affiliation":[{"name":"Department of Pharmacological Sciences, School of Pharmaceutical Sciences, Health Sciences University of Hokkaido"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinuko","family":"Koyama","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy, Hokkaido Pharmaceutical University School of Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Iizuka","sequence":"additional","affiliation":[{"name":"Department of Pharmacological Sciences, School of Pharmaceutical Sciences, Health Sciences University of Hokkaido"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Hirafuji","sequence":"additional","affiliation":[{"name":"Department of Pharmacological Sciences, School of Pharmaceutical Sciences, Health Sciences University of Hokkaido"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. <i>Support. Care Cancer<\/i>, <b>15<\/b>, 497\u2013503 (2007).","DOI":"10.1007\/s00520-006-0173-z"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Andrews PL, Naylor RJ, Joss RA. Neuropharmacology of emesis and its relevance to anti-emetic therapy. Consensus and controversies. <i>Support. Care Cancer<\/i>, <b>6<\/b>, 197\u2013203 (1998).","DOI":"10.1007\/s005200050154"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Minami M, Endo T, Hirafuji M, Hamaue N, Liu Y, Hiroshige T, Nemoto M, Saito H, Yoshioka M. Pharmacological aspects of anticancer drug-induced emesis with emphasis on serotonin release and vagal nerve activity. <i>Pharmacol. Ther.<\/i>, <b>99<\/b>, 149\u2013165 (2003).","DOI":"10.1016\/S0163-7258(03)00057-3"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Kris MG, Hesketh PJ, Herrstedt J, Rittenberg C, Einhorn LH, Grunberg S, Koeller J, Olver I, Borjeson S, Ballatori E. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. <i>Support. Care Cancer<\/i>, <b>13<\/b>, 85\u201396 (2005).","DOI":"10.1007\/s00520-004-0699-x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Gore L, Chawla S, Petrilli A, Hemenway M, Schissel D, Chua V, Carides AD, Taylor A, Devandry S, Valentine J, Evans JK, Oxenius B. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. <i>Pediatr. Blood Cancer<\/i>, <b>52<\/b>, 242\u2013247 (2009).","DOI":"10.1002\/pbc.21811"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Rudd JA, Naylor RJ. An interaction of ondansetron and dexamethasone antagonizing cisplatin-induced acute and delayed emesis in the ferret. <i>Br. J. Pharmacol.<\/i>, <b>118<\/b>, 209\u2013214 (1996).","DOI":"10.1111\/j.1476-5381.1996.tb15388.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Fukunaka N, Sagae S, Kudo R, Endo T, Hirafuji M, Minami M. Effects of granisetron and its combination with dexamethasone on cisplatin-induced delayed emesis in the ferret. <i>Gen. Pharmacol.<\/i>, <b>31<\/b>, 775\u2013781 (1998).","DOI":"10.1016\/S0306-3623(98)00102-5"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Tattersall FD, Rycroft W, Cumberbatch M, Mason G, Tye S, Williamson DJ, Hale JJ, Mills SG, Finke PE, MacCoss M, Sadowski S, Ber E, Cascieri M, Hill RG, MacIntyre DE, Hargreaves RJ. The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. <i>Neuropharmacology<\/i>, <b>39<\/b>, 652\u2013663 (2000).","DOI":"10.1016\/S0028-3908(99)00172-0"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F, Aprepitant Protocol 054 Study Group. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. <i>Cancer<\/i>, <b>97<\/b>, 3090\u20133098 (2003).","DOI":"10.1002\/cncr.11433"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin\u2014the Aprepitant Protocol 052 Study Group. <i>J. Clin. Oncol.<\/i>, <b>21<\/b>, 4112\u20134119 (2003).","DOI":"10.1200\/JCO.2003.01.095"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Schmoll HJ, Aapro MS, Poli-Bigelli S, Kim HK, Park K, Jordan K, von Pawel J, Giezek H, Ahmed T, Chan CY. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. <i>Ann. Oncol.<\/i>, <b>17<\/b>, 1000\u20131006 (2006).","DOI":"10.1093\/annonc\/mdl019"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Tan L, Liu J, Liu X, Chen J, Yan Z, Yang H, Zhang D. Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. <i>J. Exp. Clin. Cancer Res.<\/i>, <b>28<\/b>, 131 (2009).","DOI":"10.1186\/1756-9966-28-131"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Navari RM, Gray SE, Kerr AC. Olanzapine <i>versus<\/i> aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. <i>J. Support. Oncol.<\/i>, <b>9<\/b>, 188\u2013195 (2011).","DOI":"10.1016\/j.suponc.2011.05.002"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Hocking CM, Kichenadasse G. Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. <i>Support. Care Cancer<\/i>, <b>22<\/b>, 1143\u20131151 (2014).","DOI":"10.1007\/s00520-014-2138-y"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT. Radioreceptor binding profile of the atypical antipsychotic olanzapine. <i>Neuropsychopharmacology<\/i>, <b>14<\/b>, 87\u201396 (1996).","DOI":"10.1016\/0893-133X(94)00129-N"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Mitchell D, Wells C, Hoch N, Lind K, Woods SC, Mitchell LK. Poison induced pica in rats. <i>Physiol. Behav.<\/i>, <b>17<\/b>, 691\u2013697 (1976).","DOI":"10.1016\/0031-9384(76)90171-2"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Takeda N, Hasegawa S, Morita M, Matsunaga T. Pica in rats is analogous to emesis: an animal model in emesis research. <i>Pharmacol. Biochem. Behav.<\/i>, <b>45<\/b>, 817\u2013821 (1993).","DOI":"10.1016\/0091-3057(93)90126-E"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Rudd JA, Yamamoto K, Yamatodani A, Takeda N. Differential action of ondansetron and dexamethasone to modify cisplatin-induced acute and delayed kaolin consumption (\u201cpica\u201d) in rats. <i>Eur. J. Pharmacol.<\/i>, <b>454<\/b>, 47\u201352 (2002).","DOI":"10.1016\/S0014-2999(02)02472-X"},{"key":"19","unstructured":"19) Liu Y, Hamaue N, Endo T, Hirafuji M, Minami M. 5-Hydroxytryptamine (5-HT) concentrations in the hippocampus, the hypothalamus and the medulla oblongata related to cisplatin-induced pica of rats. <i>Res. Commun. Mol. Pathol. Pharmacol.<\/i>, <b>113\u2013114<\/b>, 97\u2013113 (2003)."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Yamamoto K, Nakai M, Nohara K, Yamatodani A. The anti-cancer drug-induced pica in rats is related to their clinical emetogenic potential. <i>Eur. J. Pharmacol.<\/i>, <b>554<\/b>, 34\u201339 (2007).","DOI":"10.1016\/j.ejphar.2006.09.058"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Yamamoto K, Asano K, Tasaka A, Ogura Y, Kim S, Ito Y, Yamatodani A. Involvement of substance P in the development of cisplatin-induced acute and delayed pica in rats. <i>Br. J. Pharmacol.<\/i>, <b>171<\/b>, 2888\u20132899 (2014).","DOI":"10.1111\/bph.12629"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Takano Y, Machida T, Obara Y, Hirano M, Kudo S, Takagi M, Hamaue N, Iizuka K, Hirafuji M. Methotrexate causes a change in intestinal 5-hydroxytryptamine metabolism in rats. <i>Eur. J. Pharmacol.<\/i>, <b>740<\/b>, 496\u2013503 (2014).","DOI":"10.1016\/j.ejphar.2014.06.038"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. <i>N. Engl. J. Med.<\/i>, <b>353<\/b>, 1209\u20131223 (2005).","DOI":"10.1056\/NEJMoa051688"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Koro CE, Fedder DO, L\u2019Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, Revicki DA, Buchanan RW. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. <i>BMJ<\/i>, <b>325<\/b>, 243 (2002).","DOI":"10.1136\/bmj.325.7358.243"},{"key":"25","unstructured":"25) Ebenbichler CF, Laimer M, Eder U, Mangweth B, Weiss E, Hofer A, Hummer M, Kemmler G, Lechleitner M, Patsch JR, Fleischhacker WW. Olanzapine induces insulin resistance: results from a prospective study. <i>J. Clin. Psychiatry<\/i>, <b>64<\/b>, 1436\u20131439 (2003)."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Ozasa R, Okada T, Nadanaka S, Nagamine T, Zyryanova A, Harding H, Ron D, Mori K. The antipsychotic olanzapine induces apoptosis in insulin-secreting pancreatic \u03b2 cells by blocking PERK-mediated translational attenuation. <i>Cell Struct. Funct.<\/i>, <b>38<\/b>, 183\u2013195 (2013).","DOI":"10.1247\/csf.13012"},{"key":"27","unstructured":"27) Roila F, Hesketh PJ, Herrstedt J. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. <i>Ann. Oncol.<\/i>, <b>17<\/b>, 20\u201328 (2006)."},{"key":"28","unstructured":"28) Herrstedt J, Roila F. Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. <i>Ann. Oncol.<\/i>, <b>19<\/b> (Suppl 2), 110\u2013112 (2008)."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Pf\u00fctzner A, Forst T. Elevated intact proinsulin levels are indicative of beta-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazone. <i>J. Diabetes Sci. Tech.<\/i>, <b>5<\/b>, 784\u2013793 (2011).","DOI":"10.1177\/193229681100500333"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Yamamoto K, Asano K, Matsukawa N, Imaizumi M, Yamatodani A. Time\u2013course analysis of pica in rats using an automatic feeding monitoring system. <i>J. Pharmacol. Toxicol. Methods<\/i>, <b>63<\/b>, 30\u201334 (2011).","DOI":"10.1016\/j.vascn.2010.04.011"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Tatsushima Y, Egashira N, Matsushita N, Kurobe K, Kawashiri T, Yano T, Oishi R. Pemirolast reduces cisplatin-induced kaolin intake in rats. <i>Eur. J. Pharmacol.<\/i>, <b>66<\/b>, 57\u201362 (2011).","DOI":"10.1016\/j.ejphar.2011.04.026"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Shobo M, Yamada H, Mihara T, Kondo Y, Irie M, Harada K, Ni K, Matsuoka N, Kayama Y. Two models for weight gain and hyperphasia as side effects of atypical antispychotics in male rats: validation with olanzapine and ziprasidone. <i>Behav. Brain Res.<\/i>, <b>216<\/b>, 561\u2013568 (2011).","DOI":"10.1016\/j.bbr.2010.08.046"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Sejima E, Yamauchi A, Nishioku T, Koga M, Nakagama K, Dohgu S, Futagami K, Kataoka Y. A role for hypothalamic AMP-activated protein kinase in the mediation of hyperphagia and weight gain induced by chronic treatment with olanzapine in female rats. <i>Cell. Mol. Neurobiol.<\/i>, <b>31<\/b>, 985\u2013989 (2011).","DOI":"10.1007\/s10571-011-9663-8"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Navari RM, Nagy CK, Gray SE. The use of olanzapine <i>versus<\/i> metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. <i>Support. Care Cancer<\/i>, <b>21<\/b>, 1655\u20131663 (2013).","DOI":"10.1007\/s00520-012-1710-6"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Miner WD, Sanger GJ. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. <i>Br. J. Pharmacol.<\/i>, <b>88<\/b>, 497\u2013499 (1986).","DOI":"10.1111\/j.1476-5381.1986.tb10228.x"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. <i>Acta Psychiatr. Scand.<\/i>, <b>100<\/b>, 3\u201316 (1999).","DOI":"10.1111\/j.1600-0447.1999.tb10908.x"},{"key":"37","unstructured":"37) Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain: a comprehensive research synthesis. <i>Am. J. Psychiatry<\/i>, <b>156<\/b>, 1686\u20131696 (1999)."},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man. <i>Diabetologia<\/i>, <b>28<\/b>, 412\u2013419 (1985).","DOI":"10.1007\/BF00280883"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. <i>Diabetes Care<\/i>, <b>27<\/b>, 1487\u20131495 (2004).","DOI":"10.2337\/diacare.27.6.1487"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Pf\u00fctzner A, Pf\u00fctzner AH, Larbig M, Forst T. Role of intact proinsulin in diagnosis and treatment of type 2 diabetes mellitus. <i>Diabetes Technol. Ther.<\/i>, <b>6<\/b>, 405\u2013412 (2004).","DOI":"10.1089\/152091504774198124"},{"key":"41","unstructured":"41) Pf\u00fctzner A, Kann PH, Pf\u00fctzner AH, Kunt T, Larbig M, Weber MM, Forst T. Intact and total proinsulin: new aspects for diagnosis and treatment of type 2 diabetes mellitus and insulin resistance. <i>Clin. Lab.<\/i>, <b>50<\/b>, 567\u2013573 (2004)."},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Couper GW, McAteer D, Wallis F, Norton M, Welch A, Nicolson M, Park KG. Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer. <i>Br. J. Surg.<\/i>, <b>85<\/b>, 1403\u20131406 (1998).","DOI":"10.1046\/j.1365-2168.1998.00963.x"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Suttie SA, Park KG, Smith TA. [<sup>18<\/sup>F]2-Fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells <i>in vitro<\/i> during response to epirubicin, cisplatin and 5-fluorouracil. <i>Br. J. Cancer<\/i>, <b>97<\/b>, 902\u2013909 (2007).","DOI":"10.1038\/sj.bjc.6603971"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Egawa-Takata T, Endo H, Fujita M, Ueda Y, Miyatake T, Okuyama H, Yoshino K, Kamiura S, Enomoto T, Kimura T, Inoue M. Early reduction of glucose uptake after cisplatin treatment is a marker of cisplatin sensitivity in ovarian cancer. <i>Cancer Sci.<\/i>, <b>101<\/b>, 2171\u20132178 (2010).","DOI":"10.1111\/j.1349-7006.2010.01670.x"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Galloway JA, Hooper SA, Spradlin CT, Howey DC, Frank BH, Bowsher RR, Anderson JH. Biosynthetic human proinsulin. Review of chemistry, <i>in vitro<\/i> and <i>in vivo<\/i> receptor binding, animal and human pharmacology studies, and clinical trial experience. <i>Diabetes Care<\/i>, <b>15<\/b>, 666\u2013692 (1992).","DOI":"10.2337\/diacare.15.5.666"}],"container-title":["Biological &amp; Pharmaceutical Bulletin","Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/38\/4\/38_b14-00745\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T14:33:07Z","timestamp":1566484387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/38\/4\/38_b14-00745\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b14-00745","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}